11/15
08:03 am
imux
Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]
Medium
Report
Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]
11/13
05:33 pm
imux
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]
Medium
Report
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]
11/13
06:30 am
imux
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Medium
Report
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
11/11
11:15 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/11
10:00 am
imux
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
Medium
Report
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
11/9
08:10 am
imux
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges [Yahoo! Finance]
Low
Report
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges [Yahoo! Finance]
11/7
06:30 am
imux
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/31
06:30 am
imux
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Medium
Report
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
10/29
06:30 am
imux
Immunic to Participate in Industry, Scientific and Investor Conferences in November
Low
Report
Immunic to Participate in Industry, Scientific and Investor Conferences in November
10/22
06:30 am
imux
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
High
Report
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
10/14
10:42 am
imux
Multiple Sclerosis Drug Pipeline Research Report 2024: Therapeutic Assessment, Emerging Drugs, Pipeline Development Activities, Competitive Landscape [Yahoo! Finance]
Low
Report
Multiple Sclerosis Drug Pipeline Research Report 2024: Therapeutic Assessment, Emerging Drugs, Pipeline Development Activities, Competitive Landscape [Yahoo! Finance]
9/18
06:30 am
imux
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
High
Report
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
9/17
05:43 am
imux
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
9/11
09:04 am
imux
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX), [Yahoo! Finance]
Medium
Report
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX), [Yahoo! Finance]
9/10
05:56 am
imux
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
9/9
08:45 am
imux
Immunic, Inc. (NASDAQ: IMUX) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $5.00 price target on the stock.
Low
Report
Immunic, Inc. (NASDAQ: IMUX) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $5.00 price target on the stock.
9/4
06:30 am
imux
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Low
Report
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
8/28
06:40 am
imux
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September [Yahoo! Finance]
Neutral
Report
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September [Yahoo! Finance]
8/28
06:30 am
imux
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
Neutral
Report
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
8/27
08:09 am
imux
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at B. Riley. They set a "buy" rating and a $6.00 price target on the stock.
High
Report
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at B. Riley. They set a "buy" rating and a $6.00 price target on the stock.